Aarti Drugs Chairman Retires; CFO Promoted to MD

Change in Director / Key Managerial Personnel

A) Cessation of Shri Prakash M. Patil

Nature of change: Resignation and cessation from all positions.

Name and DIN: Shri Prakash Moreshwar Patil (DIN: 00005618).

Effective date: Ceased to hold the positions of Chairman, Managing Director and Chief Executive Officer with effect from the close of business hours on September 30, 2026.

Reason for change: Early retirement. His original term was scheduled to expire on May 31, 2027. He confirmed there are no material reasons for his resignation other than his desire for an orderly leadership transition.

Previous KMP: Shri Prakash M. Patil was the previous Chairman, Managing Director and Chief Executive Officer.

B) Relinquishment of office of Chief Financial Officer by Shri Adhish P. Patil

Nature of change: Relinquishment of the CFO role due to promotion.

Name: Shri Adhish Prakash Patil.

Effective date: Relinquished the position of Chief Financial Officer with effect from the close of business hours on September 30, 2026.

Reason for change: Consequent upon his promotion (appointment) as Managing Director of the Company with effect from October 1, 2026, which was approved by shareholders at the 41st Annual General Meeting held on September 26, 2026.

Future Responsibilities: Shri Adhish P. Patil stated he shall continue to support and oversee the functions under the purview of CFO along with his responsibilities as the Managing Director.

Previous KMP: Shri Adhish P. Patil was the previous Chief Financial Officer.

Key Financial or Operational Approvals

This disclosure does not contain information on financial results, fundraising, capex, or other operational approvals beyond the management changes.

Strategic or Business Context

The change is framed as an "orderly leadership transition." The outgoing Chairman & MD, Shri Prakash M. Patil, expressed his belief that this was an "appropriate time" for this transition and that he will "remain connected with the progress of Aarti Drugs."

Any Other Material Information

Regulatory Compliance: The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and references SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Future Appointment: The Company will appoint a new Chief Financial Officer "in due course," in compliance with Regulation 26A(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company Representative: The letter is signed by Rushikesh Deole, Company Secretary & Compliance Officer (ICSI M. No.: F12932).